Baidu
map

JACC:外周动脉疾病患者血运重建后的远期预后研究

2018-08-25 MedSci MedSci原创

血运重建对外周动脉疾病患者症状的改善尤为重要,但目前尚缺乏术后主要不良肢体事件(MALE)和远期预后的资料。本研究的目的旨在评估外周动脉疾病患者血运重建后的预后情况和与MALR相关的因素分析。本研究纳入了数据库中2009年1月至2014年九月接受外周动脉血运重建的患者,并对其术后1年MALE结局进行评估,次要终点事件包括1年内门诊血管内血运重建、肢体相关住院率、心血管相关住院率和全因住院率。最终,

血运重建对外周动脉疾病患者症状的改善尤为重要,但目前尚缺乏术后主要不良肢体事件(MALE)和远期预后的资料。本研究的目的旨在评估外周动脉疾病患者血运重建后的预后情况和与MALR相关的因素分析。

本研究纳入了数据库中2009年1月至2014年九月接受外周动脉血运重建的患者,并对其术后1年MALE结局进行评估,次要终点事件包括1年内门诊血管内血运重建、肢体相关住院率、血管相关住院率和全因住院率。最终,共纳入了381415名接受血运重建的患者,在术后1年内期间,有10.3% (n = 10182)患者因MALE住院,11.0% (n = 42056)患者接受门诊血管内血运重建,18.8% (n = 71663)患者因肢体相关原因住院,12.8% (n = 48875)患者因心血管原因住院,38.9% (n = 148457)患者因任何其他原因住院。在研究期间,肢体相关住院率、心血管相关住院率和全因住院率呈下降趋势,而门诊血管内血运重建逐渐增多。与MALE发生风险增高相关的因素有:男性、黑色人种、医疗保险、糖尿病、肾功能不足、心衰、抽烟、严重或急性的肢体缺血和外科血运重建等。

研究结果显示,在外周动脉疾病患者中,血运重建术后1年内的MALE发生率约为十分之一,并与一系列患者和操作因素相关。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1984378, encodeId=e54819843e8e8, content=<a href='/topic/show?id=c4bb9443038' target=_blank style='color:#2F92EE;'>#远期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94430, encryptionId=c4bb9443038, topicName=远期预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Sun Jun 09 16:21:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799054, encodeId=80fc1e99054a0, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sat Dec 15 20:21:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854141, encodeId=08de185414181, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Jun 20 22:21:00 CST 2019, time=2019-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325948, encodeId=bb371325948cd, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Aug 27 11:21:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593305, encodeId=89ec1593305d5, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Mon Aug 27 11:21:00 CST 2018, time=2018-08-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1984378, encodeId=e54819843e8e8, content=<a href='/topic/show?id=c4bb9443038' target=_blank style='color:#2F92EE;'>#远期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94430, encryptionId=c4bb9443038, topicName=远期预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Sun Jun 09 16:21:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799054, encodeId=80fc1e99054a0, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sat Dec 15 20:21:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854141, encodeId=08de185414181, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Jun 20 22:21:00 CST 2019, time=2019-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325948, encodeId=bb371325948cd, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Aug 27 11:21:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593305, encodeId=89ec1593305d5, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Mon Aug 27 11:21:00 CST 2018, time=2018-08-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1984378, encodeId=e54819843e8e8, content=<a href='/topic/show?id=c4bb9443038' target=_blank style='color:#2F92EE;'>#远期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94430, encryptionId=c4bb9443038, topicName=远期预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Sun Jun 09 16:21:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799054, encodeId=80fc1e99054a0, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sat Dec 15 20:21:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854141, encodeId=08de185414181, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Jun 20 22:21:00 CST 2019, time=2019-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325948, encodeId=bb371325948cd, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Aug 27 11:21:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593305, encodeId=89ec1593305d5, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Mon Aug 27 11:21:00 CST 2018, time=2018-08-27, status=1, ipAttribution=)]
    2019-06-20 hbwxf
  4. [GetPortalCommentsPageByObjectIdResponse(id=1984378, encodeId=e54819843e8e8, content=<a href='/topic/show?id=c4bb9443038' target=_blank style='color:#2F92EE;'>#远期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94430, encryptionId=c4bb9443038, topicName=远期预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Sun Jun 09 16:21:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799054, encodeId=80fc1e99054a0, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sat Dec 15 20:21:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854141, encodeId=08de185414181, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Jun 20 22:21:00 CST 2019, time=2019-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325948, encodeId=bb371325948cd, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Aug 27 11:21:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593305, encodeId=89ec1593305d5, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Mon Aug 27 11:21:00 CST 2018, time=2018-08-27, status=1, ipAttribution=)]
    2018-08-27 智智灵药
  5. [GetPortalCommentsPageByObjectIdResponse(id=1984378, encodeId=e54819843e8e8, content=<a href='/topic/show?id=c4bb9443038' target=_blank style='color:#2F92EE;'>#远期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94430, encryptionId=c4bb9443038, topicName=远期预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Sun Jun 09 16:21:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799054, encodeId=80fc1e99054a0, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sat Dec 15 20:21:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854141, encodeId=08de185414181, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Jun 20 22:21:00 CST 2019, time=2019-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325948, encodeId=bb371325948cd, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Aug 27 11:21:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593305, encodeId=89ec1593305d5, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Mon Aug 27 11:21:00 CST 2018, time=2018-08-27, status=1, ipAttribution=)]

相关资讯

盘点:JACC8月第3期研究一览

1. 二尖瓣反流患者中的左室纤维化情况DOI: 10.1016/j.jacc.2018.06.048http://www.onlinejacc.org/content/72/8/823近期有研究报道原发性二尖瓣反流(MR)患者的左室纤维化主要是由二尖瓣脱垂(MVP)导致。本研究的目的旨在通过心血管磁共振(CMR)评估MR伴有MVP或者不伴有MVP患者的左室纤维化的发生率、临床特征和预后。本研究

JACC:稳定性冠心病患者应不应该接受介入治疗?

最近,经皮冠脉介入治疗(PCI)的治疗效益在稳定性冠心病(SCD)患者中存在争议。本研究的目的旨在评估PCI对SCD患者锻炼后的冠脉循环、微循环和全身血液动力学的影响。本研究对21例SCD伴单支冠脉狭窄的患者(平均年龄60.3 ± 8.4岁)进行了心导管术。PCI术前,患者在仰卧测力计上运动直至心绞痛或筋疲力尽,在运动的同时对狭窄的冠脉血流进行测量,PCI术后同样做此操作,并比较术前和术后患者的生

Am J Cardiol:使用水烟并不会降低心血管疾病风险

近日,在线发表于《American Journal of Cardiology》杂志上的一项研究表明,抽1.5h的水烟所带来的心血管危险因素(心率、血压、动脉硬化程度、血液尼古丁水平升高)与一根普通烟类似。

JACC:GATA3阳性巨噬细胞在心梗后重塑中的作用研究

巨噬细胞在心血管疾病的病理发生过程中起到重要作用。本研究的目的旨在探究GATA3阳性巨噬细胞在心梗后调节心脏功能方面的作用。本研究的小鼠模型为骨髓特异性敲除GATA3小鼠(mGATA3KO),心梗建模后,通过超声心动图对其进行心功能评估。结果发现,急性心梗建模后,GATA3阳性巨噬细胞在梗死区域快速聚集,GATA3阳性巨噬细胞的减少可以明显提高心梗后的心脏功能,这种心功能的改善与mGATA3KO小

Circulation:他汀类药物降低甘油三酯脂蛋白胆固醇的同时亦可降低心血管疾病风险

孟德尔随机数据表明,终身高甘油三酯脂蛋白胆固醇(TRL-C)的遗传决定因素与心血管疾病息息相关,因此可能是潜在的治疗靶点。在服用他汀类药物的患者中,TRL-C与心血管风险的相关性尚不明确。现研究人员对TRL-C和心血管风险之间的关系以及这种风险在他汀类药物治疗的患者中是否会发生改变进行评估。本试验招募冠心病和低密度脂蛋白胆固醇(LDL-C)水平在130-25-mg/dL的患者,进行8周的磨合期,予

JACC:机械相关并发症在STEMI患者中的的变化趋势研究

再灌注治疗大大降低了ST段抬高型心肌梗塞(STEMI)后的死亡率。本研究的目的旨在评估机械性相关并发症(MCs)随时间的发病率、管理和死亡率,以及其对老年STEMI患者短期死亡率的影响。本研究对1988年至2008年期间的1393名年龄≥75岁的新发STEMI患者进行了MCs的发病率和死亡率的分析。分析结果显示,院内死亡率从34.3%降低至13.4%(p < 0.001)。尽管由MC导致的绝

Baidu
map
Baidu
map
Baidu
map